Results 1 to 10 of about 84,596 (182)

Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model [PDF]

BMC Ophthalmology, 2009
Background Benzalkonium chloride (BAC) is a common preservative used in ophthalmic solutions. The aim of this study was to compare the cytotoxic effects of BAC-containing ophthalmic solutions with a BAC-free ophthalmic solution using an organotypic 3 ...
Jessen Bart A, Khoh-Reiter Su
doaj   +2 more sources

Vision rehabilitation of post-Descemet membrane endothelial keratoplasty Pseudomonas keratitis utilizing losartan ophthalmic solution and scleral contact lens: a case report [PDF]

Journal of Medical Case Reports
Background Descemet membrane endothelial keratoplasty is a preferred treatment for endothelial dysfunction, but complications, such as graft detachment and Pseudomonas keratitis, may affect results.
Nir Erdinest, Nadav Shemesh, Naomi London, Itay Lavy   +3 more
doaj   +2 more sources

Synergic Effect of Methyl-β-Cyclodextrin and Hydrophilic Polymers on Nepafenac Solubilization: Development of a 0.3% Ophthalmic Solution [PDF]

Molecules
Nepafenac is an anti-inflammatory drug used in ophthalmology, marketed as a suspension due to its low aqueous solubility. A solution formulation could provide better bioavailability than suspension and facilitate single unit doses, avoiding the use of ...
Maria Grazia Saita, Fabiola Spitaleri, Katia Mangano, Danilo Aleo, Angela Patti   +4 more
doaj   +2 more sources

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis [PDF]

BMC Ophthalmology, 2023
Background Dry eye disease (DED) is a disorder characterized by loss of tear film homeostasis that causes ocular surface inflammation and damage. The incidence of DED increases with age.
Paul Karpecki, Victoria Barghout, Brad Schenkel, Lynn Huynh, Anamika Khanal, Brittany Mitchell, Mihran Yenikomshian, Enrico Zanardo, Cynthia Matossian   +8 more
doaj   +2 more sources

Influence of filtering on the effective concentration and sterility of a 2% cyclosporine ophthalmic solution: a quality improvement perspective [PDF]

Journal of Pharmaceutical Health Care and Sciences, 2023
Background Pharmaceutical companies do not sell formulations for all diseases; thus, healthcare workers have to treat some diseases by concocting in-hospital preparations.
Masakazu Ozaki, Toshihiko Kobayashi, Aki Fujinaga, Mitsuaki Nishioka, Kyoko Shikichi, Satoshi Okano, Yasuhito Sakai, Sayumi Fujii, Nobuaki Matsui, Miwako Takasago, Naoto Okada, Takahiro Yamasaki, Takashi Kitahara   +12 more
doaj   +2 more sources

Impact of pH modification of the empirically used tobramycin ophthalmic solution on MIC90 concentration in tears and aqueous humor of donkeys (Equus asinus) [PDF]

BMC Veterinary Research
Background Commercial tobramycin ophthalmic solution is frequently used empirically to treat ocular disorders in equines, despite being primarily formulated for use in humans.
Ahmed Ibrahim, Mohamed A. A. Abd-Elrasoul, Mahmoud S. Sabra   +2 more
doaj   +2 more sources

Effects of model tear proteins and topical ophthalmic formulations on evaporation inhibition and biophysical property of model tear lipid nanofilm in vitro

JCIS Open, 2021
Hypothesis: Biophysical property and water evaporation retardation through a lipid nanofilm can be altered by model tear protein and topical ophthalmic formulation.
Meng C. Lin, Tatyana F. Svitova
doaj   +1 more source

Comparative Evaluation of Antimicrobial, Antiamoebic, and Antiviral Efficacy of Ophthalmic Formulations

Microorganisms, 2022
The extensive use of ophthalmic antibiotics is contributing to the appearance of resistant bacterial strains, which require prolonged and massive treatments with consequent detrimental outcomes and adverse effects.
Ciro Caruso, Daniela Eletto, Alessandra Tosco, Martina Pannetta, Fabio Scarinci, Mario Troisi, Amalia Porta   +6 more
doaj   +1 more source

Physicochemical Stability of a Novel Tacrolimus Ophthalmic Formulation for the Treatment of Ophthalmic Inflammatory Diseases

Pharmaceutics, 2022
Tacrolimus is an immunosuppressant used to treat a large variety of inflammatory or immunity-mediated ophthalmic diseases. However, there are currently no commercial industrial forms available that can provide relief to patients.
Marion Barrieu, Philip Chennell, Mouloud Yessaad, Yassine Bouattour, Mathieu Wasiak, Mireille Jouannet, Yoann Le Basle, Valérie Sautou   +7 more
doaj   +1 more source

A Randomized, Double-Blinded, Placebo-Controlled, Cross Over Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine [PDF]

, 2020
Introduction. Daily oral beta-adrenoreceptor antagonist has been shown to be effective in preventing migraine headaches. Timolol 0.5% ophthalmic solution is a non-selective beta-adrenoreceptor antago- nist, where the primary use is for glaucoma.
Aggarwal, Dipika, Barohn, Richard J., Bittel, Brennen, Dubinsky, Richard, Ford, Deetra, Gronseth, Gary, Hairston, Vernita, Heim, Andrew J., Herbelin, Laura, Landazuri, Patrick, Sachen, Fred   +10 more
core   +2 more sources